Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The Kennedy Trust has announced Dr Stephen Simpson as its new Chief Executive Officer from 1 July 2022.

Dr Stephen Simpson and Pierre Espinasse
Dr Stephen Simpson (L) has taken on the role of CEO from Pierre Espinasse (R)

Stephen has taken over the leadership of the Trust from Pierre Espinasse who managed operations at the charity since 2011. The Trust has evolved considerably under Pierre's expert guidance, most notably through its support of the Kennedy Institute's relocation from Imperial College London to its current site at the heart of the University of Oxford's Old Road Campus.

Pierre has also overseen significant funding and support initiatives at the Kennedy Institute including a pledge of £20M over five years to support pioneering research into chronic inflammatory disease, and funding to establish the Career Development Programme, enabling early career researchers to take the first step in running their own lab. The Kennedy Institute also benefits from some of the Trust's key external funding initiatives, spearheaded by Pierre, including the £2.5M Senior Research Fellowship programme launched in 2017 and the MB PhD scheme which will provide funding for 75 students over 7 years across the universities of Manchester, Birmingham, Oxford, Glasgow and Edinburgh.

Professor Dame Fiona Powrie, Director of the Kennedy Institute, added "Pierre has provided vital support to the Kennedy Institute for more than a decade. We wish him all the best for the future, and we look forward to continuing our close relationship with the Kennedy Trust under the expert leadership of Stephen Simpson."

Stephen joins the Trust with a background in medical research and in life sciences research funding. Most recently, Stephen was Director of Research at Versus Arthritis, where he led teams in the development and implementation of research, including new areas of research translation and partnership funding. During his time at the charity, Stephen championed the development of musculoskeletal research through the creation of new funding initiatives and the promotion of pain research and patient involvement.

See more on the Kennedy Trust website

Similar stories

The Kennedy’s research strongly endorsed following independent review

We recently welcomed our Scientific Advisory Board (SAB) and the Kennedy Trust Scientific Review Board (TSRB) to the Institute to review our current activities and future plans.

Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease

Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.

Mathematician boosts data science research at the Kennedy Institute

Welcome to Yang Luo who has joined the Kennedy Institute as the Principal Investigator of the Luo Group. Her lab is leading the investigation into how genetic variations contribute to diseases of the immune system.

NIHR funding for musculoskeletal and inflammatory disease research

Health and care research in Oxford is to receive £122 million in government funding over the next five years to improve diagnosis, treatment and care for NHS patients.

Leducq Foundation grant boosts cardiovascular research

The Leducq Foundation has awarded $7.5 million to researchers at the University of Oxford and their collaborators to advance immunotherapy as a treatment for cardiovascular disease, the leading cause of death in the UK.

Breakthrough in treatment for Dupuytren’s disease

Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.